Systemic scleroderma
Systemic scleroderma | |
---|---|
Other names | Diffuse scleroderma, systemic sclerosis, Curzio's Syndrome |
Clinical appearance of acrosclerotic piece-meal necrosis of the thumb in a patient with systemic sclerosis. | |
Specialty | Rheumatology |
Systemic scleroderma, or systemic sclerosis, is an
Survival rates have greatly increased with effective treatment for kidney failure. Therapies include immunosuppressive drugs, and in some cases, glucocorticoids.[2]
Signs and symptoms
) are associated with limited scleroderma. Other symptoms include:Skin symptoms
In the skin, systemic sclerosis causes hardening and scarring. The skin may appear tight, reddish, or scaly. Blood vessels may also be more visible. Where large areas are affected, fat and muscle wastage may weaken limbs and affect appearance. Patients report severe and recurrent itching of large skin areas. The severity of these symptoms varies greatly among patients: Some having scleroderma of only a limited area of the skin (such as the fingers) and little involvement of the underlying tissue, while others have progressive skin involvement.[3] Digital ulcers—open wounds especially on fingertips and less commonly the knuckles—are not uncommon.[4]
Other organs
Diffuse scleroderma can cause
- Musculoskeletal
The first joint symptoms that patients with scleroderma have are typically nonspecific joint pains, which can lead to arthritis, or cause discomfort in tendons or muscles.[5] Joint mobility, especially of the small joints of the hand, may be restricted by calcinosis or skin thickening.[7] Patients may develop muscle weakness, or myopathy, either from the disease or its treatments.[8]
- Lungs
Some impairment in lung function is almost universally seen in patients with diffuse scleroderma on
- Digestive tract
Diffuse scleroderma can affect any part of the gastrointestinal tract.
Scleroderma can decrease motility anywhere in the gastrointestinal tract.[10] The most common source of decreased motility is the esophagus and the lower esophageal sphincter, leading to dysphagia and chest pain. As scleroderma progresses, esophageal involvement from abnormalities in decreased motility may worsen due to progressive fibrosis (scarring). If this is left untreated, acid from the stomach can back up into the esophagus, causing esophagitis and gastroesophageal reflux disease. Further scarring from acid damage to the lower esophagus many times leads to the development of fibrotic narrowing, also known as strictures, which can be treated by dilatation[citation needed].
In patients with neuromuscular disorders, particularly progressive systemic sclerosis and visceral myopathy, the duodenum is frequently involved. Dilatation may occur, which is often more pronounced in the second, third, and fourth parts. The dilated duodenum may be slow to empty, and the grossly dilated, atonic organ may produce a sump effect.[citation needed]
The
Rarer complications include
Scleroderma may also be associated with
- Kidneys
Kidney involvement, in scleroderma, is considered a poor prognostic factor and frequently a cause of death.[13]
The most important clinical complication of scleroderma involving the kidney is scleroderma renal crisis (SRC), the symptoms of which are
In the past, SRC was almost uniformly fatal.
Treatments for SRC include ACE inhibitors. Prophylactic use of ACE inhibitors is currently not recommended, as recent data suggest a poorer prognosis in patient treated with these drugs prior to the development of renal crisis.[23][unreliable medical source?] Transplanted kidneys are known to be affected by scleroderma, and patients with early-onset renal disease (within one year of the scleroderma diagnosis) are thought to have the highest risk for recurrence.[24]
Causes
No clear cause for scleroderma and systemic sclerosis has been identified. Genetic predisposition appears to be limited, as genetic concordance is small; still, a familial predisposition for autoimmune disease is often seen. Polymorphisms in
One of the suspected mechanisms behind the autoimmune phenomenon is the existence of microchimerism, i.e. fetal cells circulating in maternal blood, triggering an immune reaction to what is perceived as foreign material.[26][27]
A distinct form of scleroderma and systemic sclerosis may develop in patients with
Bleomycin[33] (a chemotherapeutic agent) and possibly taxane chemotherapy[34] may cause scleroderma, and occupational exposure to solvents has been linked to an increased risk of systemic sclerosis.[35]
Pathophysiology
Overproduction of collagen is thought to result from an autoimmune dysfunction, in which the immune system starts to attack the kinetochore of the chromosomes. This would lead to genetic malfunction of nearby genes. T cells accumulate in the skin; these are thought to secrete cytokines and other proteins that stimulate collagen deposition. Stimulation of the fibroblast, in particular, seems to be crucial to the disease process, and studies have converged on the potential factors that produce this effect.[26]
A significant player in the process is
Damage to endothelium is an early abnormality in the development of scleroderma, and this, too, seems to be due to collagen accumulation by fibroblasts, although direct alterations by cytokines, platelet adhesion, and a type II hypersensitivity reaction similarly have been implicated. Increased endothelin and decreased vasodilation have been documented.[26]
Jimenez and Derk[26] describe three theories about the development of scleroderma:
- The abnormalities are primarily due to a physical agent, and all other changes are secondary or reactive to this direct insult.
- The initial event is fetomaternal cell transfer causing microchimerism, with a second summative cause (e.g. environmental) leading to the actual development of the disease.
- Physical causes lead to phenotypic alterations in susceptible cells (e.g. due to genetic makeup), which then effectuate DNA changes that alter the cells' behavior.
Diagnosis
In 1980, the American College of Rheumatology agreed on diagnostic criteria for scleroderma.[37]
Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anticentromere and anti-scl70/antitopoisomerase antibodies), and occasionally by biopsy. Of the antibodies, 90% have a detectable antinuclear antibody. Anticentromere antibody is more common in the limited form (80–90%) than in the diffuse form (10%), and anti-scl70 is more common in the diffuse form (30–40%) and in African-American patients (who are more susceptible to the systemic form).[26]
Other conditions may mimic systemic sclerosis by causing hardening of the skin. Diagnostic hints that another disorder is responsible include the absence of Raynaud's phenomenon, a lack of abnormalities in the skin on the hands, a lack of internal organ involvement, and a normal antinuclear antibodies test result.[38]
Treatment
No cure for scleroderma is known, though treatments exist for some of the symptoms, including drugs that soften the skin and reduce inflammation. Some patients may benefit from exposure to heat.[39] Holistic care of patients comprising patient education tailored to patients' education level is useful in view of the complex nature of the disease symptoms and progress.[40]
Topical/symptomatic
Topical treatment for the skin changes of scleroderma do not alter the disease course, but may improve pain and ulceration. A range of
Kidney disease
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis that may be the initial manifestation of the disease. Renal vascular injury (due in part to collagen deposition) leads to renal ischemia, which results in activation of the renin-angiotensin-aldosterone system (RAAS). This raises blood pressure and further damages the renal vasculature, causing a vicious cycle of worsening hypertension and renal dysfunction (e.g., elevated creatinine, edema). Hypertensive emergency with end-organ dysfunction (e.g., encephalopathy, retinal hemorrhage) is common. Thrombocytopenia and microangiopathic hemolytic anemia can be seen. Urinalysis is usually normal but may show mild proteinuria, as in this patient; casts are unexpected.[citation needed]
The mainstay of therapy for SRC includes ACE inhibitors, which reduce RAAS activity and improve renal function and blood pressure. Short-acting ACE inhibitors (typically captopril) are used because they can be rapidly uptitrated. An elevated serum creatinine level is not a contraindication for ACE inhibitors in this population, and slight elevations in creatinine are common during drug initiation.
Scleroderma renal crisis, the occurrence of
Lung disease
Active alveolitis is often treated with pulses of cyclophosphamide, often together with a small dose of steroids. The benefit of this intervention is modest.[42][43]
Pulmonary hypertension may be treated with
Other
Some evidence indicates that plasmapheresis (therapeutic plasma exchange) can be used to treat the systemic form of scleroderma. In Italy, it is a government-approved treatment option. This is done by replacing blood plasma with a fluid consisting of albumin, and is thought to keep the disease at bay by reducing the circulation of scleroderma autoantibodies.[46]
Epidemiology
Systemic scleroderma is a rare disease, with an annual incidence that varies in different populations. Estimates of incidence (new cases per million people) range from 3.7 to 43 in the United Kingdom and Europe, 7.2 in Japan, 10.9 in Taiwan, 12.0 to 22.8 in Australia, 13.9 to 21.0 in the United States, and 21.2 in Buenos Aires.[47] The interval of peak onset starts at age 30[48] and ends at age 50.[48]
Globally, estimates of prevalence vary from 31.0 to 658.6 affected people per million.[47] Systemic sclerosis has a female:male ratio of 3:1 (8:1 in mid- to late childbearing years). Incidence is twice as high among African Americans. Full-blooded Choctaw Native Americans in Oklahoma have the highest prevalence in the world (469 per 100,000).[49]
The disease has some hereditary association. It may also be caused by an immune reaction to a virus (molecular mimicry) or by toxins.[2]
Society and culture
Support groups
The Juvenile Scleroderma Network is an organization dedicated to providing emotional support and educational information to parents and their children living with juvenile scleroderma, supporting pediatric research to identify the cause of and the cure for juvenile scleroderma, and enhancing public awareness.[50]
In the US, the Scleroderma Foundation is dedicated to raise awareness of the disease and assist those who are affected.[51]
The Scleroderma Research Foundation sponsors research into the condition.[52] Comedian and television presenter Bob Saget, a board member of the SRF, directed the 1996 ABC TV movie For Hope, starring Dana Delany, which depicts a young woman fatally affected by scleroderma; the film was based on the experiences of Saget's sister Gay.[53]
Scleroderma and Raynaud's UK is a British charity formed by the merger of two smaller organisations in 2016 to provide support for people with scleroderma and fund research into the condition.[54][55]
Prognosis
A 2018 study placed 10-year survival rates at 88%, without differentiation based on subtype. Diffuse systemic sclerosis, internal organ complications, and older age at diagnosis are associated with worse prognoses.[56]
Research
Given the difficulty in treating scleroderma, treatments with a smaller
Autologous hematopoietic stem cell transplantation (HSCT) is based on the assumption that autoimmune diseases such as systemic sclerosis occur when the white blood cells of the immune system attack the body. In this treatment, stem cells from the patient's blood are extracted and stored to preserve them. The patient's white blood cells are destroyed with cyclophosphamide and rabbit antibodies against the white blood cells. Then, the stored blood is returned to the patient's bloodstream to reconstitute a healthy blood and immune system that will not attack the body. The results of a phase-III trial, the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, with 156 patients, were published in 2014. HSCT itself has a high treatment mortality, so in the first year, the survival of patients in the treatment group was lower than the placebo group, but at the end of 10 years, the survival in the treatment group was significantly higher. The authors concluded that HSCT could be effective, if limited to patients who were healthy enough to survive HSCT itself. Therefore, HSCT should be given early in the progression of the disease, before it does damage. Patients with heart disease, and patients who smoked cigarettes, were less likely to survive.[57][58] Another trial, the Stem Cell Transplant vs. Cyclophosphamide (SCOT) trial, is ongoing.[59]
References
- PMID 23576072.
- ^ ISBN 978-0-07-174889-6.
- PMID 18953973.
- PMID 26109864.
- ^ ISBN 978-1-912423-16-3.
- ^ "Limited Scleroderma". www.mayoclinic.org. Mayo Clinic. Retrieved 6 June 2019.
- PMID 12473275.
- PMID 8923596.
- PMID 16357695.
- ^ S2CID 46188776.
- ^ PMID 9891698.
- S2CID 31418099.
- PMID 12546318.
- PMID 12889219.
- S2CID 906790.
- PMID 12841297.
- S2CID 37453739.
- S2CID 29564540. Archived from the original(PDF) on 19 June 2015.
- S2CID 23093684.
- PMID 19487221.
- ^ Jimenez S, Koenig AS. Scleroderma. eMedicine.com. Accessed: May 22, 2006.
- PMID 17601770.
- PMID 24176729.
- S2CID 36783555.
- PMID 10609071.
- ^ PMID 14706971.
- PMID 10751084.
- PMID 20299369.
- PMID 20120045.
- PMID 20118047.
- PMID 20063400.
- PMID 17109993.
- PMID 15633728.
- S2CID 11105198.
- PMID 17117485.
- S2CID 7042371.
- PMID 7378088. Available online at "1980 Criteria for the Classification of Systemic Sclerosis". Archived from the originalon 2007-10-15. Retrieved 2007-08-05.
- ^ Moenning R, Grau RG (March 30, 2009). "Skin hardening, but is it systemic sclerosis?". The Journal of Musculoskeletal Medicine. Archived from the original on May 5, 2009. Retrieved August 27, 2009.
- S2CID 25010323.
- ^ Philip J. Clements; Daniel E. Furst. Systemic Sclerosis, 2nd ed., Chapt. 23 (PDF).
- ^ PMID 16295521.
- PMID 16790698.
- PMID 17133610.
- ^ Commissioner, Office of the (2020-02-20). "FDA approves first treatment for patients with rare type of lung disease". FDA. Retrieved 2020-02-25.
- ^ "FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD". www.boehringer-ingelheim.com. Retrieved 2022-11-30.
- S2CID 79950781.
- ^ S2CID 24050211.
- ^ a b Systemic sclerosis (scleroderma) and pregnancy By Bonnie L Bermas, MD. Retrieved on Dec 13, 2009
- PMID 8702445.
- ^ "Juvenile Scleroderma Network". Retrieved 2008-05-11.
- ^ "Scleroderma Foundation". Retrieved 2008-05-11.
- ^ "Scleroderma Research Foundation". Retrieved 2008-05-11..
- IMDb
- ^ "SRUK – Scleroderma & Raynaud's UK | SRUK". www.sruk.co.uk.
- ^ "NHS Choices Scleroderma". Retrieved 26 September 2015.
- PMID 30348207.
- PMID 25058081.
- S2CID 205060178.
- ^ Stem Cell Transplant vs. Cyclophosphamide (SCOT), NCT00114530